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Summary at a glance 
A novel marker of cystic fibrosis (CF) lung disease severity, inspiratory muscle 
electromyogram activity was investigated in 20 adult CF patients. Both TLCO 
%predicted and inspiratory muscle electromyogram activity related strongly to 
exercise performance and therefore may be useful in CF lung disease management. 
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ABSTRACT 
Background and objective 
Peak aerobic capacity (VO2peak) is an important outcome measure in cystic fibrosis (CF) 
but measurement is not widely available and can be influenced by patient motivation, 
pain and fatigue.  Alternative markers of disease severity would be helpful.  Neural 
respiratory drive, measured using parasternal intercostal muscle electromyography 
(EMGpara) reflects the load to capacity balance of the respiratory system and provides 
a composite measure of pulmonary function impairment in CF.  The aim of the study 
was to investigate the relationship between exercise capacity, EMGpara and established 
measures of pulmonary function in clinically stable adult CF patients. 
Methods 
Twenty CF patients (12 male, median (range) age 22.3 (17.0-43.1) years) performed the 
10m incremental shuttle walk test (ISWT) with contemporaneous measures of aerobic 
metabolism.  EMGpara was recorded from second intercostal space at rest and 
normalised using the peak EMG obtained during maximum respiratory manoeuvres and 
expressed as EMGpara%max. 
Results 
VO2peak was strongly correlated with ISWT distance (r=0.864, p<0.0001).  TLCO 
%predicted was best correlated with VO2peak (r=0.842, p<0.0001) and ISWT distance 
(r=0.788, p<0.0001).  EMGpara%max also correlated with VO2peak (-0.757, p<0.0001), 
while the relationships between exercise outcome measures and FEV1 %predicted and 
FVC %predicted were less strong. A TLCO %predicted of <70.5%was the strongest 
predictor of VO2peak <32ml/min/kg, (AUC 0.96, 100% sensitivity, 83.3% specificity).  
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ISWT distance and EMGpara%max also performed well, with other pulmonary function 
variables demonstrating poorer predictive ability.   
Conclusion 
TLCO% predicted and EMGpara%max relate strongly to exercise performance markers 
in CF and may provide alternative predictors of lung disease progression. 
 
Keywords: cystic fibrosis, disease management, electromyography, exercise, intercostal 
muscles, respiratory function 
 
Short title: Disease severity in Cystic Fibrosis 
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INTRODUCTION 
Forced expiratory volume in one second (FEV1) and the rate of its decline are the most 
commonly used clinical predictors of survival in cystic fibrosis (CF)1-3.  FEV1 is, however, 
effort and technique dependent, relatively insensitive to small treatment responses4 
and poorly related to symptoms5.  Recent advances in CF care, have highlighted the 
prognostic insensitivity of FEV16.  Lung clearance index (LCI) is more sensitive to changes 
in CF lung disease severity than FEV17, but measurement remains limited primarily to 
the research setting.   
 
The significant load imposed on the cardiovascular and respiratory systems during 
exercise testing can reveal pathophysiological changes associated with disease 
progression that are not detected using spirometry.  Peak aerobic capacity (VO2peak) is 
related to quality of life8, and is a strong predictor of hospitalisation9 and mortality10, 11 
in adult CF patients.  Exercise testing, however, not only requires specialist equipment 
and personnel, but also significant patient motivation.  Some individuals are unable to 
exercise maximally due to pain and fatigue.   
 
Indices which reflect both the airways obstruction and lung hyperinflation that occur in 
CF lung disease may provide more accurate markers of disease severity.  Measurement 
of neural respiratory drive (NRD), obtained during resting tidal breathing using the 
parasternal intercostal electromyogram (EMGpara), has been shown to provide a 
sensitive, easily applied indicator of load on the respiratory system that reflects lung 
disease severity in CF12, 13.  We wished, therefore, to test the hypothesis that indices 
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which reflect the overall impact of the pathophysiological changes that occur in CF lung 
disease would most strongly relate to exercise performance as assessed by the 10m 
incremental shuttle walk test (ISWT), in clinically stable adult CF patients and could, 
therefore, provide more robust markers of disease severity in CF. 
 
 
METHODS 
 
Clinically stable adult CF patients were recruited from Kings College Hospital, London, 
between January-July 2014.  The study received local research ethics committee 
approval (South London (Dulwich) LREC Ref No 05/Q0703/82) and written informed 
consent was obtained. 
 
 
Measurements 
 
Spirometry, lung gas transfer (TLCO) and its components (transfer coefficient (KCO) and 
alveolar volume (Va)) and lung volumes using body plethysmography were measured 
(Jaeger Masterscreen, CareFusion, Germany).  Height and weight were measured and 
body mass index (BMI) calculated.  Fat free mass (FFM) was determined by bioelectrical 
impedance (Bodystat 1500, Bodystat Ltd., Isle of Man, UK). 
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Surface EMGpara was recorded from the second intercostal space as previously 
described 12.  Resting EMGpara was measured during five minutes of relaxed breathing 
and the average value per breath calculated from the final minute.  EMGpara was 
expressed as a percentage of the maximum value (EMGpara%max) achieved during a 
maximal volitional inspiratory manoeuvre. Three manoeuvres were performed at least 
five times; inhalation to total lung capacity (TLC) from functional residual capacity (FRC), 
maximal inspiratory pressure (PImax) and maximal sniff nasal pressure (SNIP).  Maximal 
pressures were recorded for Pimax and SNIP. The greatest peak EMGpara regardless of 
the manoeuvre performed was selected to normalise EMGpara12, 14. For more details, 
see Supplementary Appendix S1. 
 
Exercise capacity was assessed using the incremental shuttle walking test (ISWT) as 
previously described15 with the distance achieved recorded.  During the ISWT, 
ventilatory and metabolic variables were measured using a portable exercise system 
(Metamax 3b, Cortex Medical, Germany) and oxygen saturation recorded using pulse 
oximetry. 
 
Protocol 
 
All measurements were made during a single visit.  EMGpara was measured initially 
followed by the maximal inspiratory manoeuvres, then pulmonary function followed by 
the ISWT. 
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Data analysis 
 
All data expressed as median (range).  Relationships between variables were assessed 
using Spearman correlation analysis.  Change from rest to end exercise assessed using 
Wilcoxon matched pairs signed rank test.  Mann-Whitney was used to compare variables 
between patients with a VO2peak >32ml/min/kg to those with a VO2peak <32ml/min/kg.  
Receiver operator characteristic (ROC) analysis was used to evaluate the predictive 
power of variables with respect to VO2peak<32ml/min/kg, using thresholds 
demonstrating optimum balance between sensitivity and specificity.  Statistical analysis 
performed using Prism version 6.0 (GraphPad Software Inc., California, USA).  A p value 
<0.05 was considered statistically significant, except for correlation analysis for which a 
p value <0.01 was used to allow for the number of comparisons performed. 
Mean (SD) EMGpara%max was 13.4 (7) in 15 patients with CF12.  Studying 20 patients 
would provide a representative sample with a 5% margin of error at the 10% level. 
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RESULTS 
 
Twenty adult patients, median (range) age 22.3 (17.0 - 43.1) years (12 male), with stable 
CF were studied (Table 1).  The patients had a range of disease severity as classified using 
FEV1 z-score.  Five had mild (median (range) FEV1 %predicted 95.2% (89.7 – 101.3)), 
three moderate (median (range) FEV1 %predicted 66.2% (65.0 - 68.8)), two severe 
(median (range) FEV1 %predicted 55.0% (48.3 – 61.6)) and 10 very severe airflow 
obstruction (median (range) FEV1 %predicted 38.1% (16 – 50.3)).  Gas trapping and 
hyperinflation were also present as indicated by RV/TLC >25% and TGV/TLC >50% (Table 
1). 
 
All patients performed a maximal shuttle walk test as indicated by either a respiratory 
exchange ratio (RER) >1.1 (n=14), a max HR >80% predicted (n=4) or a maximum minute 
ventilation (Vemax) >80% predicted (Predicted from FEV1 x 40) (n=2).  Median (range) 
ISWT distance was 645m (280 – 880).  All physiological variables changed significantly 
from baseline to end exercise (Table 2) (p<0.001).   
 
Median (range) VO2peak 23.9 ml/min/kg (16.8 – 38.7)) and VO2 at AT (15.2 ml/min/kg 
(10.3 – 29.5)) indicated markedly reduced exercise capacity in this patient group overall.  
A strong correlation was observed between ISWT distance and VO2peak (r=0.864, 
p<0.0001).  The relationship between VO2peak and ISWT distance was described by the 
regression equation and 95% confidence intervals VO2peak = 1.789 (-4.91 to 8.49) + 
0.0401 (0.03 to 0.05) x ISWT distance (Fig 1).   
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EMGpara%max reflected CF lung disease severity and was significantly correlated with 
TLCO %predicted, RV/TLC, FEV1 % predicted and FVC % predicted and Va %predicted 
(Table 3).  
 
TLCO %predicted showed the strongest relationship with exercise outcome measures, 
correlating significantly with VO2peak (r=0.842, p<0.0001), VO2 at AT (r=0.671, 
p=0.0012) and ISWT distance (r=0.788, p<0.0001) (Table 4).  TLCO %predicted showed 
the best correlation with end exercise SpO2 (r=0.64, p<0.01). EMGpara%max was also 
significantly correlated with VO2peak, VO2 at AT and ISWT distance walked (Table 4).  
The relationships between exercise capacity and other lung function and respiratory 
muscle parameters including FEV1 %predicted and FVC %predicted were less strong 
(Table 4).  Fat free mass correlated with ISWT distance. 
 
Using the variables that correlated with VO2peak, patients with a VO2peak 
<32ml/min/kg had significantly higher EMGpara%max at rest and lower TLCO 
%predicted, ISWT distance and FVC %predicted than those with VO2peak >32ml/min/kg 
(Fig 2).  Thresholds for predicting VO2peak <32ml/min/kg, together with sensitivity and 
specificity values and area under the ROC curve for each measured variable are shown 
in Table 5. A TLCO %predicted of <70.5%was the strongest predictor of VO2peak 
<32ml/min/kg, (AUC 0.96, 100% sensitivity, 83.3% specificity).  ISWT and EMGpara%max 
also performed well, with other variables demonstrating poorer predictive ability (Table 
5). 
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DISCUSSION 
 
The study examined the relationship between exercise capacity, EMGpara activity and 
pulmonary function in adult CF patients.  EMGpara%max and TLCO %predicted were 
more strongly related to measures of exercise performance than FEV1.  TLCO %predicted 
was most strongly related to VO2peak and ISWT distance and most accurately predicted 
VO2peak. 
 
Exercise capacity was assessed using the ISWT with contemporaneous measurements 
of respiratory and metabolic variables.  The ISWT has been shown to provide a valid 
assessment of maximal exercise capacity in individuals with chronic respiratory 
diseases16, 17. Patients performed the ISWT maximally and each test was conducted by 
an experienced practitioner.  Although the ISWT was performed once only, all 
participants were accustomed to the test as part of their routine clinical assessment.  
Contemporaneous measurement of metabolic variables avoided comparison between 
results of exercise tests performed on two separate occasions.  Exercise limitation in 
CF is multifactorial hence not all patients will demonstrate respiratory limitation at end 
exercise, however each patient was deemed to have reached limitation by at least one 
of the described criteria: RER >1.1 representing metabolic limitation, HR 
>80%predicted representing cardiac limitation or Vemax >80%predicted representing 
ventilatory limitation.   
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To reduce contamination from adjacent postural muscles and ensure good quality 
EMGpara signals were acquired, patients adopted a relaxed seated position with arms 
supported and adaptive mains filtering and post-acquisition digital band-pass filtering 
were applied to minimise background electrical noise.  Standardised electrode position 
and good electrical contact were adopted to minimise poor between-subject and 
between-occasion reproducibility18.  EMG signal attenuation due to subcutaneous fat 
was not considered important as none of the patients were obese.   
 
As expected, a strong correlation between ISWT distance and VO2peak was observed 
and the data broadly comparable to those obtained by Bradley et al19 (r=0.95, p<0.01) 
using a modified ISWT19.  When compared in percentage terms to these data19, the 
steeper slope and lower intercept of the regression equation derived from the current 
data resulted in slightly lower values for VO2peak at the shorter ISWT distances (90% at 
300m) and higher values at the longer ISWT distances (118% at 900m).  These 
differences probably reflect the use of the modified ISWT by Bradley et al and the 
inclusion of patients with greater exercise tolerance and higher VO2peak.   
 
Measures of exercise capacity were also strongly correlated with a number of 
pulmonary function variables and EMGpara%max.  Overall, VO2peak, VO2 at AT and 
ISWT distance were most strongly correlated with TLCO %predicted.  The strength of the 
relationship between TLCO %predicted and VO2peak (r=0.842) was similar to that 
observed between ISWT distance and VO2peak (r=0.864), suggesting TLCO could be a 
useful marker of lung disease severity in CF patients particularly in those that are unable 
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or unwilling to exercise maximally.  Similar, albeit less strong relationships were 
observed between EMGpara%max, VO2peak, VO2 at AT and ISWT distance.  Interestingly 
FEV1 and RV/TLC were only moderately well correlated with markers of exercise 
capacity, reflecting previous findings on the strength of the relationships observed 
between pulmonary function and exercise performance 6, 19.. 
 
Pianosi et al demonstrated that a VO2peak <32ml/min/kg was associated with a 60% 
eight-year mortality in CF10.  Our data indicated that patients with a VO2peak 
<32ml/min/kg had significantly lower levels of TLCO %predicted and higher levels of 
EMGpara%max as well as decreased ISWT distance, FEV1 %predicted and FVC 
%predicted.  Receiver operator curve analysis indicated TLCO %predicted <70.2% was 
the strongest predictor of a VO2peak <32ml/min/kg.  Both ISWT distance and 
EMGpara%max also had good positive predictive accuracy, while FVC %predicted and 
FEV1%predicted performed less well.  The relatively poorer predictive capacity of 
spirometric variables was most likely due to such measures only representing one aspect 
of the pathophysiological changes that occur in CF lung disease and hence do not fully 
reflect the range of factors which limit exercise in this patient group. 
 
There are few data available concerning the relationship between exercise performance 
and TLCO in CF.  Pastre et al20 demonstrated that TLCO and FEV1 correlated with 
VO2peak, but that FEV1 demonstrated the strongest relationship.  The study did, 
however, involve bootstrapping to account for missing data for some variables including 
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TLCO.  Our results are similar in that FEV1 did correlate with VO2peak, but that TLCO 
%predicted had the strongest relationship.   
 
Exercise tolerance in CF is multifactorial, only 30% of the variability in exercise 
performance has been attributed to airways obstruction20-23.  Gas exchange 
abnormalities have also been shown to affect exercise performance24-26.  Small airway 
dysfunction leading to ventilation heterogeneity and ventilation perfusion mismatch 
alongside elevated venous admixture, intrapulmonary shunting and alveolar 
hypoventilation7, 27, 28 have been implicated.  TLCO reflects the lung volume available 
for gas exchange, gas diffusion and exchange across the alveolar membrane.  In 
worsening CF lung disease, accessible alveolar volume decreases due to ventilation 
heterogeneity and gas diffusion is impaired by suboptimal ventilation/perfusion 
relationships.  By contrast gas exchange across the alveolar membrane is not 
substantially reduced, as demonstrated in the current cohort by the relatively well 
preserved KCO.  When considered alongside the measured reductions in alveolar 
volume and the relationship of Va %predicted to VO2peak and VO2 at AT and the 
relationship between TLCO% predicted and end exercise SpO2, the current data 
suggest that it is the decreased accessible lung volume and impaired gas diffusion as 
measured using TLCO that contributed mostly to exercise impairment in this cohort of 
CF patients rather than airways obstruction. 
 
The parasternal intercostal muscles are obligate inspiratory muscles recruited in 
tandem with the diaphragm, acting to prevent rib cage distortion and ventilatory 
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inefficiency.  EMGpara increases progressively alongside diaphragm EMG during 
exercise12.  EMGpara provides a measure of NRD which, unlike measures such as 
spirometry which only measures a single aspect of respiratory function, reflects the 
combined effects of mechanical and metabolic load on the respiratory system.  In CF, 
airways obstruction and lung hyperinflation increase the load on the respiratory 
muscles.  Lung hyperinflation increases the elastic work of breathing and the 
development of intrinsic positive end-expiratory pressure which imposes a threshold 
load on each breath.  Hyperinflation also reduces inspiratory muscle length leading to 
functional inspiratory muscle weakness29.  NRD as measured by EMGpara increases to 
maintain ventilation at the appropriate level for blood gas homeostasis.  The current 
data confirm our previous findings that EMGpara%max provides a sensitive indicator 
of load on the respiratory system which is related to disease severity in CF12, 13 and 
demonstrate that this index provides an effort independent measure of exercise 
capacity which could be helpful in disease management. 
 
EMGpara%max and TLCO %predicted were also strongly correlated with each other.  
As median KCO %predicted for the group was 99% and not significantly related to 
EMGpara%max, the current data suggest that the significant relationship between 
TLCO %predicted and EMGpara%max was primarily due to decrements in alveolar 
volume available for gas exchange.  A significant correlation between EMGpara%max 
and Va %predicted was observed. 
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Although exercise limitation in CF has a large ventilatory component, it is also influenced 
by peripheral muscle function30-32 and nutritional status 21 as indicated by the significant 
correlation between FFM and ISWT distance.  Suboptimal peripheral muscle function 
results in decreased aerobic metabolism and early lactic acidaemia23, 31, resulting in 
reduced exercise capacity.  Although TLCO and EMGpara%max were strongly correlated 
with physiological measures of exercise capacity, such measurements were performed 
at rest and therefore do not reflect both the influence of peripheral muscle dysfunction 
and the changes in lung function such as dynamic hyperinflation 12 that occur during 
exercise which influence exercise performance. 
 
TLCO is not routinely measured in CF and is not part of CF care standards 33.  There is 
conflicting evidence as to the benefit of measuring TLCO in patients with CF.  TLCO has 
been shown to be maintained until lung disease becomes more advanced34 and hence 
is unhelpful prognostically35.  Conversely, serial measurements have been shown to 
correlate with clinical severity in patients with advanced lung disease, unlike routine 
lung function tests such as FEV136, 37.  Although lung function indices such as FEV1 and 
FVC are commonly used to assess CF lung disease severity, assessment of exercise 
performance is a key clinical and trial outcome tool in CF 33, 38 and measurement of 
VO2peak has been shown to better predict both mortality 10, 11, 39 and the risk of 
hospitalisation9.  Exercise testing with the aim of measuring VO2peak is, however, 
expensive and demanding on patients and therefore not always utilised in CF centres.  
This study has shown that measurements of TLCO %predicted, as well EMGpara%max 
were strongly related to exercise performance.   
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In conclusion, measurement of peak aerobic capacity is an important assessment tool in 
CF management. It is, however, not widely available and such testing can be negatively 
influenced by poor patient motivation, pain, fatigue as well as shortness of breath.  
Integrated measures of pulmonary function such as TLCO %predicted and 
EMGpara%max were related strongly to exercise performance in adult patients with CF 
and therefore may be of benefit in the assessment of CF lung disease severity.   
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Table 1. Patient characteristics, pulmonary function and exercise performance in 20 
adult patients with CF. 
 Median (range) 
Age (years) 22.3(17.0 - 43.2) 
Height (cm) 169.9 (150.1 - 178.4) 
Weight (kg) 56.6 (47.3 - 73.3) 
BMI (kg/m2) 19.9 (18.0 - 27.2) 
FFM (%) 80.0 (59.4 – 91.9) 
FEV1 %predicted 49.3(16.0 - 101.3) 
FVC %predicted 76.5 (23.8 - 111.9) 
RV/TLC (%) 44.0 (22.0 - 74.0) 
TGV/TLC (%) 61.0 (43.0 - 79.0) 
TLCO %predicted 70.5 (41.1 - 104.1) 
KCO %predicted 98.8 (70.6 - 127.4) 
Va %predicted 75.7 (33.2 – 126.8) 
Pimax (cmH2O) 99.9 (61.1 – 130.0) 
SNIP (cmH2O) 94.0 (40.61 – 128.6) 
 
BMI body mass index, FFM fat free mass, FEV1, forced expired volume in 1 second, FVC 
forced vital capacity, RV residual volume, TLC total lung capacity, TGV thoracic gas 
volume, TLCO lung gas transfer, KCO transfer coefficient, Va alveolar volume, Pimax 
maximal inspiratory pressure, SNIP sniff nasal inspiratory pressure) 
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Table 2. Median (range) rest and end exercise data for ISWT, VO2peak, VCO2peak, RER, 
Ve/VO2, Ve/VCO2, Ve %predicted, heart rate, SpO2 and EMGpara%max.   
Variable Resting End Exercise p 
ISWT distance (m)  645m (280 – 880)  
VO2peak(ml/min/kg) 5.8 (4.3 - 8.1) 24.4 (16.8 - 38.7) <0.001 
VCO2peak(ml/min/kg) 4.7 (3.1 - 7.1) 24.9 (14.1 - 42.5) <0.001 
RER 0.83 (0.62 - 0.94) 1.09 (0.8 - 1.46) <0.001 
Ve/VO2  35.15 (25.1 – 45.6)  
Ve/VCO2  32.7 (24.6 – 48.8)  
Ve (%pred.) 12.0 (4.9 - 41.9) 63.7 (43.0 - 114.0) <0.001 
HR (bpm) 86.5(60 - 110) 161 (125 – 175) <0.001 
SpO2 96 (88 – 100) 93 (70 – 97) < 0.001 
EMGpara%max (%) 7.8 (2.0 - 34.5)   
 
ISWT incremental shuttle walk test, VO2peak peak oxygen consumption, VCO2peak peak 
carbon dioxide production, RER respiratory exchange ratio, Ve minute ventilation, HR 
heart rate, SpO2 pulse oximetry derived oxygen saturation, EMGpara%max parasternal 
intercostal muscle EMG expressed as a percentage of maximum) 
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Table 3. Spearman’s correlation analysis examining the relationships between resting 
EMGpara%max and TLCO %predicted, RV/TLC, FEV1 % predicted, FVC % predicted and 
Va %predicted. 
 EMGpara%max 
 r P 
TLCO %predicted -0.78 <0.0001 
RV/TLC %predicted 0.69 0.001 
FEV1 %predicted -0.65 0.002 
Va %predicted -0.62 0.004 
FVC %predicted -0.61 0.004 
 
TLCO lung gas transfer, RV residual volume, TLC total lung capacity, FEV1, forced expired 
volume in 1 second, Va alveolar volume, FVC forced vital capacity 
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Table 4. Spearman’s correlation analysis examining the relationships of VO2peak, AT and 
ISWT distance with TLCO % predicted, resting EMGpara%max, FEV1 % predicted, FVC 
%predicted and FFM.   
 
VO2peak 
(ml/min/kg) 
VO2 at AT 
(ml/min/kg) 
ISWT Distance Walked 
(m) 
 r p r P r p 
TLCO % predicted 0.842 <0.0001 0.671 0.0012 0.788 <0.0001 
EMGpara%max -0.757 <0.0001 -0.669 0.0012 -0.720 <0.0001 
FVC %predicted 0.593 0.0058 0.666 0.0013 0.551 0.011 
FEV1 % predicted 0.558 0.011* 0.549 0.012* 0.581 0.007 
Va %predicted 0.572 0.008 0.592 0.006 0.509 0.022* 
FFM (%) 0.524 0.018* 0.295 0.207 0.628 0.003 
 
*p values less than 0.01 used to define significance due to the number of comparisons 
performed. TLCO lung gas transfer, EMGpara%max parasternal intercostal muscle EMG 
expressed as a percentage of maximum, FVC forced vital capacity, FEV1, forced expired 
volume in 1 second, Va alveolar volume, FFM fat free mass 
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Table 5. Results of ROC analysis to predict VO2peak <32 ml/min/kg.  Area under curve, 
sensitivity and specificity for TLCO %predicted, ISWT distance, EMGpara%max, FVC 
%predicted and FEV1 %predicted. 
Variable Threshold Area Sensitivity Specificity 
TLCO %predicted <70.5% 0.96 100 83.3 
ISWT  <670 m 0.93 100 84.6 
EMGpara%max >10.20% 0.92 100 76.9 
FVC  <77.7% 0.87 85.71 76.9 
FEV1 %predicted <63.30% 0.86 85.71 84.6 
Va %predicted <70.15 0.86 100 53.9 
 
TLCO lung gas transfer, ISWT incremental shuttle walk distance, EMGpara%max 
parasternal intercostal muscle EMG expressed as a percentage of maximum, FVC forced 
vital capacity, FEV1, forced expired volume in 1 second, Va alveolar volume) 
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Figure legends 
 
Figure 1.  Regression analysis describing the relationship between VO2peak and ISWT 
distance.  Dashed line lines represent 95% confidence intervals.  Regression equation 
(95%CI) VO2peak = 1.789 (-4.91 to 8.49) + 0.0401 (0.03 to 0.05) x ISWT distance 
 
 
Figure 2. Comparison of EMGpara%max, TLCO, ISWT and FVC %predicted and FEV1 
%predicted in patients achieving a VO2peak <32ml/min/kg with those of >32ml/min/kg.  
Horizontal lines indicate median 
 
